Prostacyclin synthase gene transfer inhibits neointimal formation in rat balloon-injured arteries without bleeding complications

Cardiovascular Research

Volumn 43, Issue 2, 1999, Pages 481-491

  Harada, Mitsunori ^a   Toki, Yukio ^a   Numaguchi, Yasushi ^a   Osanai, Hiroyuki ^a   Ito, Takayuki ^a   Okumura, Kenji ^a   Hayakawa, Tetsuo ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arteries; Gene therapy; Hemostasis; Prostaglandins; Rat; Restenosis

Indexed keywords

BERAPROST; PLASMID DNA; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN;

ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BLEEDING; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ANALYSIS OF VARIANCE; ANIMALS; BALLOON DILATATION; BLOTTING, WESTERN; CELL DIVISION; CYTOCHROME P-450 ENZYME SYSTEM; EPOPROSTENOL; GENE TRANSFER TECHNIQUES; INTRAMOLECULAR OXIDOREDUCTASES; MUSCLE, SMOOTH, VASCULAR; PLATELET AGGREGATION INHIBITORS; RATS; TUNICA INTIMA;

EID: 0033178929     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00107-8     Document Type: Article

References (41)

1. Strauss W.E., Fortin T., Hartigan P., Folland E.D., Parisi A.F. Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators. A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy: outcomes of a randomized clinical trial. Circulation. 92:1995;1710-1719.
2. Landau C., Lange R.A., Hillis L.D. Percutaneous transluminal coronary angioplasty. N Engl J Med. 330:1994;981-993.
3. King S.B. III., Lembo N.J., Weintraub W.S., et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med. 331:1994;1044-1050.
4. Califf R.M., Fortin D.F., Frid D.J., et al. Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol. 17:1991;2B-13B.
5. Herrman J.-P.R., Hermans W.R.M., Vos J., Serruys P.W. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the holy grail? Drugs. 46:(Pt I):1993;18-52.
6. Muller D.W.M., Ellis S.G., Topol E.J. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 19:1992;418-432.
7. Mintz G.S., Popma J.J., Pichard A.D., et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 94:1996;35-43.
8. Di Mario C., Gil R., Camenzind E., et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol. 75:1995;772-777.
9. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
10. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 331:1994;496-501.
11. Powell J.S., Clozel J.-P., Müller R.K., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 245:1989;186-188.
12. 1 receptor antagonist. Am J Pathol. 139:1991;1291-1296.
13. Matsuno H., Kozawa O., Niwa M., Uematsu T. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation. 96:1997;1299-1304.
14. Chang M.W., Barr E., Seltzer J., et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:1995;518-522.
15. Indolfi C., Avvedimento E.V., Rapacciuolo A., et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1:1995;541-545.
16. von der Leyen H.E., Gibbons G.H., Morishita R., et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 92:1995;1137-1141.
17. Lam J.Y.T., Chesebro J.H., Badimon L., Fuster V. Exogenous prostacyclin decreases vasoconstriction but not platelet thrombus deposition after arterial injury. J Am Coll Cardiol. 21:1993;488-492.
18. 2 on platelet aggregation in different species. Prostaglandins. 16:1978;373-387.
19. Jones D.A., Benjamin C.W., Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol. 48:1995;890-896.
20. Asada Y., Kisanuki A., Hatakeyama K., et al. Inhibitory effects of prostacyclin analogue, TFC-132, on aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro. Prostaglandins Leukotrienes Essent Fatty Acids. 51:1994;245-248.
21. 2 analogue) in the atherosclerotic rabbit artery after angioplasty. J Cardiovasc Pharmacol. 25:1995;947-952.
22. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomized placebo controlled trial. Br Heart J. 71:1994;7-15.
23. Tone Y., Inoue H., Hara S., et al. The regional distribution and cellular localization of mRNA encoding rat prostacyclin synthase. Eur J Cell Biol. 72:1997;268-277.
24. Ueno H., Haruno A., Morisaki N., et al. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation. 96:1997;2272-2279.
25. Zoldhelyi P., McNatt J., Xu X.M., et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 93:1996;10-17.
26. Miano J.M., Tota R.R., Vlasic N., Danishefsky K.J., Stemerman M.B. Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal. Am J Pathol. 137:1990;761-765.
27. Asahara T., Bauters C., Pastore C., et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 91:1995;2793-2801.
28. Libby P., Schwartz D., Brogi E., Tanaka H., Clinton S.K. A cascade model for restenosis-A special case of atherosclerosis progression. Circulation. 86:1992;47-52.
29. Bath P.M.W., Hassall D.G., Gladwin A., Palmer R.M.J., Martin J.F. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb. 11:1991;254-260.
30. Willis A.L., Smith D.L., Vigo C., et al. Orally active prostacyclin-mimetic RS-93427: therapeutic potential in vascular occlusive disease associated with atherosclerosis. Prostaglandin Thromboxane Leukotriene Res. 17A:1987;254-265.
31. 2) in man. Br J Clin Pharmacol. 14:1982;177-185.
32. Baek S., March K.L. Gene therapy for restenosis getting nearer the heart of the matter. Circ Res. 82:1998;295-305.
33. Guzman R.J., Hirschowitz E.A., Brody S.L., et al. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA. 91:1994;10732-10736.
34. Ohno T., Gordon D., San H., et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 265:1994;781-784.
35. Schulick A.H., Vassalli G., Dunn P.F., et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. 99:1997;209-219.
36. Newman K.D., Dunn P.F., Owens J.W., et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 6:1995;2955-2965.
37. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 96:1997;2280-2286.
38. Vanhoutte P.M. Endothelium-dependent contractions in arteries and veins. Blood Vessels. 24:1987;141-144.
39. 2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension. 15:1990;475-481.
40. 2 as an endothelium-derived contracting factor and its interaction with endothelium-derived nitric oxide. J Hypertens. 9:1991;729-736.
41. Pritchard K.A. Jr., O'Banion M.K., Miano J.M., et al. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Chem. 269:1994;8504-8509.